Adagrasib and pembrolizumab combination therapy achieved a median PFS of 27.7 months in KRASG12C-mutated NSCLC patients with PD-L1 ≥50%. The combination therapy showed a 59.3% overall response rate, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results